Author: Editor

Caron Jacobson, MD of Dana Farber Cancer Institute @DanaFarber discusses the interim analysis of zuma-5 presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/186013/abstract

Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184547/abstract

Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184547/abstract

Lipika Goyal, MD of Massachusetts General Hospital @MassGeneralNews discusses the data for futibatinib in advanced intrahepatic cholangiocarcinoma. Read here: https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-for-futibatinib-in-advanced-intrahepatic-cholangiocarcinoma-at-2020-asco-meeting-301068213.html?tc=eml_cleartime

Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract

Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract

Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Oncoceutics’ investigational cancer drug ONC201 for the treatment of “H3 K27M-mutant glioma”.The Rare Pediatric Disease Priority Review Voucher program, which was created as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, is intended to incentivize the development of new therapies for rare pediatric diseases. Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics…

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract

Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract

Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13029

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July and expresses its support for all those affected by this devastating form of brain cancer. Glioblastoma (GBM) is the most common type of malignant brain tumor among adults and is typically fatal. The two-year survival rate for GBM is less than 20%, and little progress has been made in battling brain cancer over the past 50 years. ONC201, the company’s lead development candidate, is currently being tested in clinical trials for brain cancer, including GBM. Early results for the ONC201 trials…

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072 presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/186711/abstract

Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a first-in-human study in patients with advanced cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185085/abstract

Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type pancreatic cancer. Read here: https://meetinglibrary.asco.org/record/186629/abstract

Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer. Read here: https://meetinglibrary.asco.org/record/185449/abstract

Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer. Read here: https://meetinglibrary.asco.org/record/185449/abstract

Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer. Read here: https://meetinglibrary.asco.org/record/188425/abstract

Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer.

Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases Read here: https://meetinglibrary.asco.org/record/185141/abstract

Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases Read here: https://meetinglibrary.asco.org/record/185141/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways.

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways. Read here: https://meetinglibrary.asco.org/record/187164/abstract

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways. Read here: https://meetinglibrary.asco.org/record/187164/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells for GBM patients https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2014-0899.html

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells for GBM patients https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2014-0899.html

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). https://meetinglibrary.asco.org/record/185977/abstract

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). https://meetinglibrary.asco.org/record/185977/abstract

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract

Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses DARolutamide observationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients. Read her: https://meetinglibrary.asco.org/record/191738/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/191796/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/191796/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC. Read here: https://meetinglibrary.asco.org/record/188306/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC. Read here: https://meetinglibrary.asco.org/record/188306/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187482/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187482/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187482/abstract

Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women.

Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women.

Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA4

Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA4

Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html

Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html

Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html

Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract

Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract

Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract

Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract

Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract

Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here: https://meetinglibrary.asco.org/record/191881/abstract

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here: https://meetinglibrary.asco.org/record/191881/abstract

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here:https://meetinglibrary.asco.org/record/191881/abstract

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here: https://meetinglibrary.asco.org/record/191881/abstract

Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract

Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract

Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract

Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm

Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm

Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm

Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Read here: https://meetinglibrary.asco.org/record/186710/abstract

Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Read here: https://meetinglibrary.asco.org/record/186710/abstract

Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.In this video, Dr. Li shares information on the role of immunotherapy for unresectable stage 3 non small cell lung cancer.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care.

Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care.

Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care. Read here: https://meetinglibrary.asco.org/record/185972/abstract

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Earn CME: https://www.naccme.com/program/20-hemcovid-7 In this webcast, Drs. Joseph R. Mikhael and Michael J. Satlin discuss new updates on the current understanding of the epidemiology and pathology of SARS-CoV-2 and outlines current treatment strategies, including the potential for interactions with anticancer agents. © 2020 Imedex, an HMP Company

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO.

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO. More here: https://www.strataoncology.com/asco20

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO. More here: https://www.strataoncology.com/asco20

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.

Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). Read here: https://meetinglibrary.asco.org/record/186864/abstract

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM.

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM. Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html

Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM. Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Earn CME: https://www.naccme.com/program/20-hemcovid-6 In this webcast, Drs. Joseph R. Mikhael and Jessica K. Altman discuss best practices for addressing current and potential challenges in the diagnosis and management of myeloid malignancies during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-5 In this webcast, Dr. Joseph R. Mikhael and patient advocate Yelak Biru discuss ways to limit patient and provider exposure to SARS-CoV-2 while effectively managing hematologic malignancies © 2020 Imedex, an HMP Company

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade treatment. Read here: https://www.eurekalert.org/pub_releases/2020-04/c-ktt042720.php

Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade treatment. Read here: https://www.eurekalert.org/pub_releases/2020-04/c-ktt042720.php

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Andrew Krivoshik, MD of Astellas @AstellasUS discusses what is net for Astellas.

Andrew Krivoshik, MD of Astellas @AstellasUS discusses the long-term results of the phase III ADMIRAL trial presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185308/abstract

Andrew Krivoshik, MD of Astellas @AstellasUS discusses the importance of the phase III PROSPER trial in the prostate cancer community presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187453/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO. ______________ Results from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session at ASCO. The study investigated pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS), higher-risk chronic myelomonocytic leukemia (HR-CMML) or low blast acute myeloid leukemia (LB-AML).These patients typically have poor prognoses as a result of limited response to available therapies. HR-MDS, in particular, has…

Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO. ______________ Results from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session at ASCO. The study investigated pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS), higher-risk chronic myelomonocytic leukemia (HR-CMML) or low blast acute myeloid leukemia (LB-AML).These patients typically have poor prognoses as a result of limited response to available therapies. HR-MDS, in particular, has…

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line  

Ross Camidge, MD, PhD on Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here:https://meetinglibrary.asco.org/record/186906/abstract  

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here: https://meetinglibrary.asco.org/record/186906/abstract

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here: https://meetinglibrary.asco.org/record/186906/abstract

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings: 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%). Fatigue…

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings:   301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%).…

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings: 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%). Fatigue…

Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/full/10.1200/JCO.20.00593

Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/full/10.1200/JCO.20.00593

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO.

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/184901/abstract

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/184901/abstract

Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer.

Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer.

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020  

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020

Earn CME: https://www.naccme.com/program/20-hemcovid-4 In this webcast, Drs. Joseph R. Mikhael leads a roundtable discussion with Drs. Jessica K. Altman, Michael Angarone, Matthew R. Levine, and Mary-Beth Percival and patient advocate Yelak Biru about management challenges faced by healthcare practitioners as they manage patients with hematologic malignancies during the COVID-19 pandemic, with a focus on the patient experience. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-3 In this webcast, Drs. Joseph R. Mikhael and Nina Shah discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with myeloma during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-2 In this webcast, Drs. Joseph R. Mikhael and John P. Leonard discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with lymphoma during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-1 In this webcast, Drs. Joseph R. Mikhael, John P. Leonard, Nina Shan, and Michael J. Satlin discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with hematologic malignancies during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020

Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Philadelphia, PA (June 8, 2020) –  Oncoceutics announced today a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212. As part of this award, Oncoceutics has received a $1M subaward to complete the IND-enabling studies for ONC212. ONC212 will be the third imipridone to enter clinical trials for oncology and is an agonist for the G protein-coupled receptor (GPCR) GPR132 and the mitochondrial protease ClpP, both novel targets that are highly expressed in cancer cells.The award goes to…

Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the BCMA CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read here: https://meetinglibrary.asco.org/record/186155/abstract

Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read here: https://meetinglibrary.asco.org/record/186155/abstract

Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval of Rubraca in mCRPC

Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.

Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly diagnosed glioblastoma patients are alive 12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.

Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.

Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses phase 2 Study of pembro plus platinum doublet chemotherapy and radiotherapy as first-line therapy for locally advanced NSCLC presented at this year’s virtual ASCO.

Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses how patients tolerated this therapy? – Phase 2 Study of Pembro plus Platinum Doublet Chemotherapy and Radiotherapy as First-Line Therapy for Locally Advanced NSCLC.

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: Why are targeted therapies important in treating sALCL?

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: How ADCETRIS may impact the existing sALCL treatment landscape?

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: What study supported the approval of ADCETRIS for the treatment of adult patients with previously untreated sALCL?

Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.

Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.

Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the virtual 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) from Friday, May 29th to Tuesday, June 2nd that highlight the clinical safety and efficacy of ONC201 across a number of clinical trials, age groups and tumor types, including H3 K27M-mutant diffuse midline glioma. Additionally, a dedicated abstract will present the rationale and design of the first-in-human clinical trial for ONC206, the company’s second molecule of its portfolio of imipridones to enter clinical development.“The data presented at ASCO…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. Read here: https://insight.jci.org/articles/view/133920?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities….A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.”We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and find new vulnerabilities…

Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. _____________ A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. “We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and…

Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Read here: https://jitc.bmj.com/content/8/1/e000673

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class of imipridones will be presented at the 2020 annual meeting of the American Association of Cancer Research (AACR) on June 22-24, 2020. The research presented at AACR highlights the antitumor and cancer prevention activity of ONC201 in tumor types with dysregulation of its two binding targets DRD2 and ClpP: H3 K27M-mutant diffuse midline glioma, endometrial cancer, medullary thyroid cancer, small cell lung cancer, and colon cancer. The presentations further highlight novel ONC201 biomarkers that help to further inform the clinical efficacy…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html  

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…